|Day Low/High||83.83 / 85.42|
|52 Wk Low/High||65.44 / 88.76|
The medical device and health care company is set to resume its long advance, with our first price target at $92 and next at $100.
The Fed is doing this right. Let me repeat... the Fed is not screwing this up.
When you have an oversold market you've got a true coiled spring that can rally beyond where it might ordinary go on good news.
ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.
Preventing the U.S. dollar from appreciating too aggressively while repairing credit conditions are 'job freaking one'.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.
China reported positive data, bolstering markets. Netflix had a beat on earnings, but faces fierce competition ahead. CSX is a thing of beauty.
ABT is pointed up after trading in a choppy range since October.
Keeping an eye on the Senate shutdown vote and any trade discussion today, and watching key support levels on the SPX.
The kick will come from the Chinese capitulating because their economy is so weak.
Mike Cintolo and Jim Woods saw their top picks for 2018 rise 81% and 75%, respectively.
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
It becomes difficult for me to tell you where to run in these markets...
I am unimpressed by the latest earnings report. Despite good subscriber growth, fundamentals look weak.
While Abbott's charts are not screaming sells, there are enough signals to suggest a cautious approach to earnings.
PepsiCo, GE and just like the weather, the stock market is subject to change.
Straying from these names could land you in quicksand as the 4th quarter begins.
Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.
It is all about perception, and here are strong names to pick up on market weakness.
As hedge funds are forced to unwind tech positions, here is how to play the rotation.
Earnings have been strong, and analysts will soon start to concentrate more on actual weakness than shadow-boxing weakness.
If you are long ABT continue to hold and raise sell stop protection to a close below $59 or where the 200-day moving average line intersects.